KMT2A and leukemia: In fact, Issa et al. (2023) report in a phase 1 clinical trial that revumenib (SNDX-5613), a menin-MLL inhibitor, resulted in partial or complete remission in patients with relapsed or refractory NPM-1-mutated leukemia.